 buy pt watch tripl second pivot studi initi updat
model symdeko rais pt analyst jason mccarthi ph full summari
whiteston reit buy pt disappoint guidanc reduc pt discount valuat solid
engil hold inc egl hold result in-lin view book trend remain disappoint maintain
corpor event call maxim salesperson inform
cover ndr boston cfo golder wed jun
corp cover kinstling ndr boston cfo ranjan kalia wed
payment data system inc pyd ndr nyc ceo loui hoch cfo tom jewel wed
nic inc cover kinstling ndr nyc cfo steve kovzan vice-president corpor commun
corpor ctrl cover chokshi ndr boston ny cfo mark novakovich mon tue may
profir energi inc pfie host jang ndr nyc ceo brendan hatch cfo ryan oviatt wed thur
watch tripl second pivot studi initi
updat model symdeko rais pt
vertex announc initi studi evalu tripl combin
tezacaftor ivacaftor cystic fibrosi cf
patient two copi mutat homozygot
second pivot program tripl studi heterozyg patient
minim function mutat het/min also underway vertex
expect addit tripl combin studi
initi well
updat therapeut model follow symdeko approv
us cf patient age homozyg
mutat patient least one mutat respons
tez/iva approv europ expect later year model chang
includ revis homozyg market includ market share
shift orkambi symdeko symdeko access new patient price
symdeko small adjust market penetr
rate net effect higher price target
tripl combin clinic trial get smaller shorter vertex
continu develop next-gen cf regimen tripl combin back
approv medicin particularli symdeko recal orkambi studi enrol
patient symdeko studi enrol patient drug
demonstr signific improv lung function week
symdeko backbon studi het/min patient enrol patient
four-week efficaci safeti data safeti data collect
requir regulatori submiss support nda homozygot
studi tripl enrol patient four-week efficaci follow four-
week run-in period tez/iva safeti data het/min studi
support nda could see data later year studi combin
tezacaftor plan decis advanc
pivot program base data two studi demonstr
percent predict forc expiratori volum
symdeko launch underway us eu approv homozygot
patient least one mutat respons tez/iva expect
improv safeti profil orkambi patient may convert symdeko
symdeko reach homozyg patient inelig orkambi well
model updat re-evalu model includ share homozyg
market shift symdeko factor homozyg market elig
symdeko base orkambi inelig patient patient toler orkambi
new patient initi start symdeko vs orkambi combin cf revenu
slightli lower rang recent
announc compani guidanc estim orkambi
lower estim symdeko increas
conclus symdeko backbon efficaci larg
segment cf popul vertex ideal posit bring tripl combin
cf market rapidli orkambi still grow symdeko launch
tripl come vertex continu build cf franchis time could
potenti reach cf popul
click full note
disappoint guidanc reduc pt
report core ffo includ non-recur
expens versu dividend
manag gave core ffo guidanc consensu
core ffo
lower core ffo estim base
new estim lower reit valuat sinc time
previou note lower price target new price
target equat core ffo estim discount peer
reiter buy rate view sound busi model
excel manag suffici earn power cover dividend
yield expect stronger year
pillarston posit dispos develop project come
fulli line
result summari march post-clos report core fund
oper core ffo per share includ expens one-
time non-recur versu dividend ffo per share
ep
data growth expect view
aberr same-stor net oper incom noi core retail properti
wholli own grew versu adjust non-recur expens
alreadi mention increas same-stor noi properti
reflect lower occup non-cor non-retail legaci properti spun
decemb pillarston compani pillarston
result consolid
core ffo guidanc introduc rang vs
surpris investor main caus declin
stock price march mainli core ffo
consensu expect guidanc rang includ same-stor noi growth
core retail properti wholli own
pillarston continu drag deconsolid track year-end
pillarston expect continu drag intend
deconsolid pillarston year-end addit part reason
lower core ffo relat core ffo defin part effici plan
reduc expens percentag total properti revenu expect
lower total compens expens differ mix share-bas
compens decreas performance-bas cash compens increas
result lower core ffo share-bas compens add-back
ffo get core ffo lower share-bas compens less add back
disposit activ benefit intend dispos
four non-cor pillarston properti million none sold
one sold thu far million remain
three contract negoti alreadi mention also intend
deconsolid pillarston year-end dispos million ownership
interest addit intend sell core properti valu
alreadi maxim exampl list properti phoenix
sale price million compani origin acquir million
subsequ brought wal-mart groceri store anchor manag expect
use proce disposit fund development/redevelop exist
properti pay debt
develop activ benefit use land acquir
acquisit blvd place houston start build mixed-us
properti expect accret contributor noi addit
develop two adjac properti dalla bought
also accret contributor noi also shop starwood
frisco texa north dalla develop current occup
rate full year much higher occup
lower price target base lower core ffo
estim see page updat earn model
lower reit valuat jone retail reit
year-to-d last six month new price target equat
new estim core ffo view discount peer
price target could warrant account smaller rel size howev
note compar peer stronger growth profil
ecommerce-resist busi model pay much higher dividend
versu averag
reiter buy rate sound busi model excel manag
suffici earn power cover dividend well stronger year expect
much better valuat view regard march
sell-off way overdon next four quarter expect dividend yield
stock price appreci price target
result estim total return
click full note
result in-lin view book trend
revenu million year year in-lin
estim
declin result natur program complet program egl
replac small busi contractor lack new busi win
off-set headwind
compani award million new busi
award year year
manag invest strengthen busi captur team
ad incent put pressur profit expect
lead modest organ growth
manag plan submit billion propos billion
believ propos critic
maintain hold rate book trend improv
result line estim revenu million in-
line estim y/i place egl laggard among public
defens servic compani exclud divestitur complet revenu
declin egl program went small busi contractor
re-compet coupl lack new busi win natur conclus
program reason year-over-year declin adjust ebitda
million million higher estim
book trend remain disappoint compani award million
award almost re-compet new busi
win total approxim million roughli million
poor book result million worth propos get delay
expect award addit compani
success win larg intellig contract tri take away
ramp bid propos volum could help revers book trend
egl make invest strengthen busi captur capabl
new hire incent plan compani plan submit billion propos
billion billion plan
propos new busi averag win rate industri
contract attempt take-away busi incumb believ
even volum submiss necessari egl strong relationship
contrast mantech buy fastest grow feder servic contractor
public compani similar annual revenu plan submit billion
propos
fine tune ep estim reflect higher-than-expect increas
invest busi captur result lower adjust ebitda
estim million million million
million adjust ebitda guidanc million add
back stock-bas compens estim add back almost million
maintain hold rate believ manag right path still
work order improv bid propos effort strategi captur
new busi would re-evaluate thesi book improv may
suggest return organ revenu growth
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
